Business Wire

CO-TECHSTARS

6.1.2022 14:02:13 CET | Business Wire | Press release

Share
Techstars Announces Two New Executive Team Leaders: Rupa Athreya Appointed Chief Accelerator Investments Officer & Marie Moussavou Appointed Chief Portfolio Services Officer

Techstars, a global investment business that provides access to capital, one-on-one mentorship, and customized programming for early-stage entrepreneurs, has created two new leadership roles as the company continues to scale to serve more founders around the world. With $850 million in assets under management, 47 accelerator programs in 17 countries, and a global alumni base of more than 2,700 companies, both roles will provide strategic and operational support to thousands of entrepreneurs. Athreya and Moussavou will report directly to the company’s CEO, Maelle Gavet.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220106005289/en/

“Techstars has an unprecedented ability to impact entrepreneurs through our unique pre-seed investment model that identifies exceptional entrepreneurs worldwide and supports them operationally and financially as they build their businesses,” stated Gavet. “We count on globally experienced executives with the ability to think big-picture, enabling the organization to operate at scale which is why both Marie and Rupa are such wonderful additions to our global management team.”

As the company’s first Chief Accelerator Investments Officer, Rupa Athreya will lead a worldwide team of more than 75 investment professionals who represent Techstars in 37 cities around the world. Techstars operates under the principle that the best founders can come from anywhere, running programs locally in the cities where the entrepreneurs operate or seek to grow. Techstars maintains a small class size ranging from 10 to 12 portfolio companies and runs multiple programs in cities with larger entrepreneur ecosystems. Techstars’ Accelerator Investment Team invested approximately $94 million last year and will continue to grow its portfolio as investors around the world seek to invest in viable early-stage companies. Overseeing this decentralized approach requires a seasoned executive with a strategic mindset, strong operational skills and global experience.

Having worked at global firms such as OppenheimerFunds, JPMorgan Chase, Bloomberg and McKinsey, Athreya has most recently been an independent consultant advising startups and new businesses as well as global financial institutions on strategy, innovation, and go-to-market execution. She has close to 20 years of expertise in building and launching new businesses and products, having led product development at OppenheimerFunds, founded a robo-advisor at Bloomberg and launched the Chase Private Client business at JPMorgan Chase. She has a Ph.D. in Economics from Yale University, a B.A. in Philosophy, Politics and Economics from Oxford University and a B.A. in Economics from the University of Delhi. She will continue to be based out of New York, NY.

As Techstars’ first Chief Portfolio Services Officer, Marie Moussavou will be responsible for advancing growth, providing infrastructure support and investment opportunities for Techstars’ more than 6,500 alumni founders as they lead their companies through later stages. Portfolio Services provides capital and funding, business development and talent connections, mentorship, and knowledge exchange for Techstars’ network of founders, investors, mentors and innovation partners. With this ever-growing network, the Portfolio Services team under Moussavou’s leadership will maintain deep, personal relationships with founders while leveraging robust data management skills to offer founders customized and scalable support.

Moussavou has a proven track record of scaling high growth, customer-focused organizations through innovation and operational excellence. Most recently she worked at Amazon for 15 years in various senior roles, including Technical Advisor to the SVP for International, Director of Alexa Europe, and Director of Operations for Amazon Transportation Services Europe. Marie has an MBA from the London Business School and lives in London, U.K., where she will continue to be based.

About Techstars

The Techstars worldwide network helps entrepreneurs succeed. Founded in 2006, Techstars began with three simple ideas—entrepreneurs create a better future for everyone, collaboration drives innovation, and great ideas can come from anywhere. Now we are on a mission to enable every person on the planet to contribute to, and benefit from, the success of entrepreneurs. In addition to operating accelerator programs and venture capital funds, we do this by connecting startups, investors, corporations, and cities to help build thriving startup communities. Techstars has invested in more than 2,800 companies with a combined market cap of more than $195B. www.techstars.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release

Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa

EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release

EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia

Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release

Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting

FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release

FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease

Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release

Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye